November 9th- OPTIMUM/MUKnine: Can intensified, risk-adapted therapy overcome high-risk multiple myeloma? CME Congresses . November 9th- OPTIMUM/MUKnine: Can intensified, risk-adapted therapy overcome high-risk multiple myeloma? November 9th- Vers un traitement précoce du myélome multiple indolent CME Congresses . November 9th- Vers un traitement précoce du myélome multiple indolent November 5th- Beyond the Webinar: How should we manage chemotherapy-induced thrombocytopenia, or CIT, and what is the role of thrombopoietin-receptor agonists? CME Congresses . November 5th- Beyond the Webinar: How should we manage chemotherapy-induced thrombocytopenia, or CIT, and what is the role of thrombopoietin-receptor agonists? November 2nd- Thrombopénie et chimiothérapie: comment éviter les interruptions de traitement ? CME Congresses . November 2nd- Thrombopénie et chimiothérapie: comment éviter les interruptions de traitement ? November 2nd- Why is cilta-cel so effective? The CAR promoter may be part of the answer CME Congresses . November 2nd- Why is cilta-cel so effective? The CAR promoter may be part of the answer October 30th- Beyond the Webinar: Chronic GVHD: Moving Beyond Steroids Towards Precision and Personalized Treatment CME Congresses . October 30th- Beyond the Webinar: Chronic GVHD: Moving Beyond Steroids Towards Precision and Personalized Treatment October 28th- Beyond the Webinar: Anti-CD38 mAb-based strategies across the myeloma continuum CME Congresses . October 28th- Beyond the Webinar: Anti-CD38 mAb-based strategies across the myeloma continuum October 26th- From IMiDs to CELMoDs: 30 Years of Cereblon Biology in Multiple Myeloma CME Congresses . October 26th- From IMiDs to CELMoDs: 30 Years of Cereblon Biology in Multiple Myeloma October 22nd- Beyond the Webinar: CELMoDs in Multiple Myeloma: A New Era of Cereblon Modulation CME Congresses . October 22nd- Beyond the Webinar: CELMoDs in Multiple Myeloma: A New Era of Cereblon Modulation October 19th- Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma CME Congresses . October 19th- Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Page21 Page22 Page23 Page24 Page25 Page26 Page27 Page28
